Подходы к персонализации фармакотерапии антиагрегантной терапии на основе фармакогенетического тестирования у пациентов казахской национальности

1. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics — based therapeutic recommendations — ready for clinical practice? Nat Rev Drug Discov. 2005;4(8):639- 47.

2. Golukhova EZ, Ryabinina MN, Bulaeva NI. The platelet reactivity after percutaneous coronary interventionin patients with double antiplatelet therapy: impact of genetic polymorphisms. Creative Cardiology. 2013;(2):15-27. (In Russ).

3. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. Journal of the American College of Cardiology. 2012;60(3):193-199.

4. Sychev DA, Shprakh VV, Kitaeva EYu, Mirzaev KB. Polymorphism of CYP2C19and ABCB1genes associated with changes in the activity of clopidogrelin patients with ischemic stroke: clinical and ethnic aspects. Klinicheskaya farmakologiya i terapiya. 2019;28(3):79-84. (In Russ).